A detailed history of Vanguard Group Inc transactions in Context Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,744,961 shares of CNTX stock, worth $3.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,744,961
Previous 4,502,198 16.82%
Holding current value
$3.82 Million
Previous $9 Million 18.48%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.79 - $2.66 $1.36 Million - $2.01 Million
-757,237 Reduced 16.82%
3,744,961 $7.34 Million
Q2 2024

Aug 13, 2024

BUY
$1.24 - $2.19 $4.84 Million - $8.55 Million
3,903,895 Added 652.49%
4,502,198 $9 Million
Q1 2024

May 10, 2024

BUY
$0.92 - $1.38 $2,107 - $3,161
2,291 Added 0.38%
598,303 $825,000
Q4 2023

Feb 14, 2024

BUY
$0.79 - $1.41 $1,991 - $3,554
2,521 Added 0.42%
596,012 $673,000
Q3 2023

Nov 14, 2023

BUY
$0.9 - $1.59 $16,911 - $29,877
18,791 Added 3.27%
593,491 $896,000
Q2 2023

Aug 14, 2023

BUY
$0.48 - $1.6 $624 - $2,080
1,300 Added 0.23%
574,700 $919,000
Q1 2023

May 15, 2023

SELL
$0.56 - $1.06 $37,779 - $71,510
-67,463 Reduced 10.53%
573,400 $321,000
Q4 2022

Feb 10, 2023

BUY
$0.61 - $1.42 $100 - $232
164 Added 0.03%
640,863 $416,000
Q3 2022

Nov 14, 2022

BUY
$1.11 - $2.08 $13,009 - $24,377
11,720 Added 1.86%
640,699 $711,000
Q2 2022

Aug 12, 2022

BUY
$1.29 - $2.66 $506,583 - $1.04 Million
392,700 Added 166.2%
628,979 $1.33 Million
Q1 2022

May 13, 2022

BUY
$1.72 - $2.82 $37,152 - $60,912
21,600 Added 10.06%
236,279 $513,000
Q4 2021

Feb 14, 2022

BUY
$2.66 - $7.45 $571,046 - $1.6 Million
214,679 New
214,679 $571,000

Others Institutions Holding CNTX

About Context Therapeutics Inc.


  • Ticker CNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,966,100
  • Market Cap $16.3M
  • Description
  • Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therape...
More about CNTX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.